Manager × security

NOVO HOLDINGS A/S FDMT holdings history

Who else holds this security?

4D MOLECULAR THERAPEUTICS IN · CUSIP 35104E100 · CIK 1388325

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, NOVO HOLDINGS A/S reported 3.25M FDMT (shares), valued at $43.21M, or 2.51% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources
Portfolio weight and quantity history
Reported portfolio weight
2.51%
Shares
3.25M
3,249,178
Reported value
$43.21M
USD

Shares decreased 11.00%; reported value increased 27.14%, and weight changed -0.24 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20262.51%3,249,178SEC filingFiled Aug 14, 2026
Q1 20262.75%3,650,737SEC filingFiled May 15, 2026
Q4 20252.13%3,650,737SEC filingFiled Feb 17, 2026
Q3 20251.12%2,000,000SEC filingFiled Nov 14, 2025
Q2 20250.52%2,000,000SEC filingFiled Aug 14, 2025
Q1 20250.48%1,950,000SEC filingFiled May 15, 2025
Q4 20240.51%1,500,000SEC filingFiled Feb 14, 2025
Q3 20240.81%1,500,000SEC filingFiled Oct 24, 2024
Q2 20241.58%1,400,000SEC filingFiled Aug 20, 2024Amended
Q1 20243.08%1,400,000SEC filingFiled May 15, 2024
Q4 20231.88%1,500,000SEC filingFiled Feb 14, 2024
Q3 20231.13%1,200,000SEC filingFiled Nov 14, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20231.13%1,200,000$15.28MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing
Filed Nov 14, 2023
Q4 20231.88%1,500,000$30.39MShares increased 25.00%; reported value increased 98.94%, and weight changed +0.75 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Feb 14, 2024
Q1 20243.08%1,400,000$44.60MShares decreased 6.67%; reported value increased 46.77%, and weight changed +1.20 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed May 15, 2024
Q2 20241.58%1,400,000$29.39MShares unchanged; reported value decreased 34.12%, and weight changed -1.50 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Aug 20, 2024
Q3 20240.81%1,500,000$16.21MShares increased 7.14%; reported value decreased 44.82%, and weight changed -0.77 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Oct 24, 2024
Q4 20240.51%1,500,000$8.36MShares unchanged; reported value decreased 48.47%, and weight changed -0.30 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Feb 14, 2025
Q1 20250.48%1,950,000$6.30MShares increased 30.00%; reported value decreased 24.61%, and weight changed -0.03 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed May 15, 2025
Q2 20250.52%2,000,000$7.42MShares increased 2.56%; reported value increased 17.81%, and weight changed +0.04 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Aug 14, 2025
Q3 20251.12%2,000,000$17.38MShares unchanged; reported value increased 134.23%, and weight changed +0.60 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Nov 14, 2025
Q4 20252.13%3,650,737$27.38MShares increased 82.54%; reported value increased 57.54%, and weight changed +1.01 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Feb 17, 2026
Q1 20262.75%3,650,737$33.99MShares unchanged; reported value increased 24.13%, and weight changed +0.62 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed May 15, 2026
Q2 20262.51%3,249,178$43.21MShares decreased 11.00%; reported value increased 27.14%, and weight changed -0.24 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Aug 14, 2026
NOVO HOLDINGS A/S · 4D MOLECULAR THERAPEUTICS IN

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1388325","quarter":"2026Q2","cusip":"35104E100"}

get_institutional_manager_history
{"cik":"1388325","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.